193 related articles for article (PubMed ID: 17268643)
1. Synthesis, crystal structure and biological activity of beta-carboline based selective CDK4-cyclin D1 inhibitors.
García MD; Wilson AJ; Emmerson DP; Jenkins PR; Mahale S; Chaudhuri B
Org Biomol Chem; 2006 Dec; 4(24):4478-84. PubMed ID: 17268643
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological activity of new CDK4-specific inhibitors, based on fascaplysin.
Aubry C; Wilson AJ; Jenkins PR; Mahale S; Chaudhuri B; Maréchal JD; Sutcliffe MJ
Org Biomol Chem; 2006 Mar; 4(5):787-801. PubMed ID: 16493461
[TBL] [Abstract][Full Text] [Related]
3. Fascaplysin-inspired diindolyls as selective inhibitors of CDK4/cyclin D1.
Aubry C; Wilson AJ; Emmerson D; Murphy E; Chan YY; Dickens MP; García MD; Jenkins PR; Mahale S; Chaudhuri B
Bioorg Med Chem; 2009 Aug; 17(16):6073-84. PubMed ID: 19632122
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of new tryptamine and tetrahydro-beta-carboline-based selective inhibitors of CDK4.
Jenkins PR; Wilson J; Emmerson D; Garcia MD; Smith MR; Gray SJ; Britton RG; Mahale S; Chaudhuri B
Bioorg Med Chem; 2008 Aug; 16(16):7728-39. PubMed ID: 18650093
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of cancer cell growth by cyclin dependent kinase 4 inhibitors synthesized based on the structure of fascaplysin.
Mahale S; Aubry C; Jenkins PR; Maréchal JD; Sutcliffe MJ; Chaudhuri B
Bioorg Chem; 2006 Oct; 34(5):287-97. PubMed ID: 16904725
[TBL] [Abstract][Full Text] [Related]
6. New fascaplysin-based CDK4-specific inhibitors: design, synthesis and biological activity.
Aubry C; Jenkins PR; Mahale S; Chaudhuri B; Maréchal JD; Sutcliffe MJ
Chem Commun (Camb); 2004 Aug; (15):1696-7. PubMed ID: 15278142
[TBL] [Abstract][Full Text] [Related]
7. 3D-QSAR CoMFA study on indenopyrazole derivatives as cyclin dependent kinase 4 (CDK4) and cyclin dependent kinase 2 (CDK2) inhibitors.
Singh SK; Dessalew N; Bharatam PV
Eur J Med Chem; 2006 Nov; 41(11):1310-9. PubMed ID: 16890327
[TBL] [Abstract][Full Text] [Related]
8. Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors.
McInnes C; Wang S; Anderson S; O'Boyle J; Jackson W; Kontopidis G; Meades C; Mezna M; Thomas M; Wood G; Lane DP; Fischer PM
Chem Biol; 2004 Apr; 11(4):525-34. PubMed ID: 15123247
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel thieno[2,3-d]pyrimidin-4-yl hydrazone-based inhibitors of Cyclin D1-CDK4: synthesis, biological evaluation, and structure-activity relationships.
Horiuchi T; Chiba J; Uoto K; Soga T
Bioorg Med Chem Lett; 2009 Jan; 19(2):305-8. PubMed ID: 19091560
[TBL] [Abstract][Full Text] [Related]
10. 3D-QSAR and molecular docking study on bisarylmaleimide series as glycogen synthase kinase 3, cyclin dependent kinase 2 and cyclin dependent kinase 4 inhibitors: an insight into the criteria for selectivity.
Dessalew N; Bharatam PV
Eur J Med Chem; 2007 Jul; 42(7):1014-27. PubMed ID: 17335939
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and 3D-QSAR of beta-carboline derivatives as potent antitumor agents.
Cao R; Guan X; Shi B; Chen Z; Ren Z; Peng W; Song H
Eur J Med Chem; 2010 Jun; 45(6):2503-15. PubMed ID: 20304536
[TBL] [Abstract][Full Text] [Related]
12. A comparative molecular field analysis of cytotoxic beta-carboline analogs.
Hou XR; Chen Q; Cao RH; Peng WL; Xu AL
Acta Pharmacol Sin; 2004 Jul; 25(7):959-65. PubMed ID: 15210072
[TBL] [Abstract][Full Text] [Related]
13. 4-(Pyrazol-4-yl)-pyrimidines as selective inhibitors of cyclin-dependent kinase 4/6.
Cho YS; Borland M; Brain C; Chen CH; Cheng H; Chopra R; Chung K; Groarke J; He G; Hou Y; Kim S; Kovats S; Lu Y; O'Reilly M; Shen J; Smith T; Trakshel G; Vögtle M; Xu M; Xu M; Sung MJ
J Med Chem; 2010 Nov; 53(22):7938-57. PubMed ID: 21038853
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological study of novel pyrido[2,3-d]pyrimidine as anti-proliferative CDK2 inhibitors.
Ibrahim DA; Ismail NS
Eur J Med Chem; 2011 Dec; 46(12):5825-32. PubMed ID: 22000924
[TBL] [Abstract][Full Text] [Related]
15. New potential inhibitors of cyclin-dependent kinase 4: design and synthesis of pyrido[2,3-d]pyrimidine derivatives under microwave irradiation.
Tu S; Zhang J; Zhu X; Xu J; Zhang Y; Wang Q; Jia R; Jiang B; Zhang J
Bioorg Med Chem Lett; 2006 Jul; 16(13):3578-81. PubMed ID: 16621547
[TBL] [Abstract][Full Text] [Related]
16. Discovery of cyclin-dependent kinase inhibitor, CR229, using structurebased drug screening.
Kim MK; Min J; Choi BY; Lim H; Cho YH; Lee CH
J Microbiol Biotechnol; 2007 Oct; 17(10):1712-6. PubMed ID: 18156791
[TBL] [Abstract][Full Text] [Related]
17. 4-(Phenylaminomethylene)isoquinoline-1,3(2H,4H)-diones as potent and selective inhibitors of the cyclin-dependent kinase 4 (CDK4).
Tsou HR; Otteng M; Tran T; Floyd MB; Reich M; Birnberg G; Kutterer K; Ayral-Kaloustian S; Ravi M; Nilakantan R; Grillo M; McGinnis JP; Rabindran SK
J Med Chem; 2008 Jun; 51(12):3507-25. PubMed ID: 18494457
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, modeling, and RET protein kinase inhibitory activity of 3- and 4-substituted beta-carbolin-1-ones.
Cincinelli R; Cassinelli G; Dallavalle S; Lanzi C; Merlini L; Botta M; Tuccinardi T; Martinelli A; Penco S; Zunino F
J Med Chem; 2008 Dec; 51(24):7777-87. PubMed ID: 19053769
[TBL] [Abstract][Full Text] [Related]
19. Synthetic approaches to indolo[6,7-a]pyrrolo[3,4-c]carbazoles: potent cyclin D1/CDK4 inhibitors.
Faul MM; Engler TA; Sullivan KA; Grutsch JL; Clayton MT; Martinelli MJ; Pawlak JM; LeTourneau M; Coffey DS; Pedersen SW; Kolis SP; Furness K; Malhotra S; Al-awar RS; Ray JE
J Org Chem; 2004 Apr; 69(9):2967-75. PubMed ID: 15104433
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of novel amide AKT1 inhibitors with selectivity over CDK2.
Ashton KS; St Jean DJ; Poon SF; Lee MR; Allen JG; Zhang S; Lofgren JA; Zhang X; Fotsch C; Hungate R
Bioorg Med Chem Lett; 2011 Sep; 21(18):5191-6. PubMed ID: 21824779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
